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Abstract
Background—Obesity is a systemic disorder associated with an increase in left ventricular mass
and premature death and disability from cardiovascular disease. Although bariatric surgery reverses
many of the hormonal and hemodynamic derangements, the long-term collective effects on body
composition and left ventricular mass have not been considered before.
Hypothesis—The decline in fat mass and lean mass after weight loss surgery is associated with a
decline in left ventricular mass.
Methods—Fifteen severely obese women (mean body mass index or BMI: 46.7 ± 1.7 kg/m2) with
medically controlled hypertension underwent bariatric surgery. Left ventricular mass and plasma
markers of systemic metabolism, together with BMI, waist and hip circumferences, body composition
(fat mass and lean mass), and resting energy expenditure (REE) were measured at 0, 3, 9, 12 and 24
months.
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Results—Left ventricular mass continued to decline linearly over the entire period of observation,
while rates of weight-loss, loss of lean mass, loss of fat mass, and REE all plateaued at 9 months
(p<0.001 for all). Parameters of systemic metabolism normalized by 9 months, and showed no further
change at 24 months after surgery.
Conclusions—Even though parameters of obesity, including BMI and body composition, plateau,
the benefits of bariatric surgery on systemic metabolism and left ventricular mass are sustained. We
propose that the progressive decline of left ventricular mass after weight loss surgery is regulated by
neurohumoral factors, and may contribute to improved long-term survival.
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INTRODUCTION
Obesity is a systemic disorder associated with an increase in left ventricular mass and premature
death and disability from cardiovascular disease.1–3 Although bariatric surgery reverses many
of the associated hormonal and hemodynamic changes, the collective effects on body
composition and left ventricular mass have not been considered before.
Weight-loss following bariatric surgery is accompanied by significant changes in body
composition and resting energy expenditure (REE) as well as rapid reversal of insulin
resistance, of hypertension, and of many of the other obesity-related complications.4–9 Weight
loss surgery also extends the otherwise shortened life span of patients with severe obesity.3,
10 In spite of significant weight loss, many patients remain clinically obese, although the
sequelae of obesity reverse.11, 12 The effects of weight loss surgery on cardiac structure and
function have been reported before,11–16 but the long-term effects on left ventricular mass are
not known. Because ventricular hypertrophy is of adverse prognostic value for death and
disability from cardiovascular disease, 17 we asked whether bariatric surgery affects left
ventricular mass in the long term.
The goal of the present study was to compare the changes in body mass index (BMI), waist
circumference and hip circumference, fat mass, lean mass, and REE, to the changes in left
ventricular mass. We examined the different parameters over a two-year period and found that
left ventricular mass decreased linearly while other parameters, including body composition,
and metabolic homeostasis, changed in a non-linear fashion or plateaued as early as one month
after surgery.
MATERIALS AND METHODS
Subjects
Fifteen consecutive women with clinically severe obesity (BMI 46.7 kg/m2, mean age: 49.1 ±
2.1 years; 10 Caucasian, 4 African-American, 1 Hispanic), underwent bariatric surgery at the
University of Texas Medical School at Houston Bariatric Surgery Center. The subjects met
inclusion criteria published previously. 14 Exclusion criteria were: patients age less than 18
years, pregnancy, coronary artery disease, ischemic cardiomyopathy, severe peripheral
vascular disease, or a current history of smoking. The study was approved by the Committee
for the Protection Human Subjects at The University of Texas Health Science Center at
Houston. All participants signed a written informed consent. Of the 15 women, 10 underwent
laparoscopic small pouch gastric bypass with a Roux-en Y procedure while the remaining 5
underwent laparoscopic adjustable gastric banding procedure. Both procedures were
performed as described in the literature. 14, 18, 19 There were no complications with the surgery.
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There was also no significant difference between groups before and after surgery for all
parameters reported here.
Study Protocol
Subjects were analyzed at baseline, one month, three months, six months, nine months, and 24
months post surgery. Individuals were asked to fast 12 hours and abstain from alcohol and
exercise for 24 hours prior to evaluation. Each visit consisted of: a standard physical exam,
measurements of blood pressure, heart rate, and weight, as well as questions regarding eating
habits, activity level, and possible complications related to the surgery. Body composition and
resting energy expenditure (REE) were measured, blood was drawn, and an echocardiogram
was obtained at each visit.
Patient Characteristics, Body Composition and Resting Energy Expenditure
At baseline, one, three, nine and 24 months we measured body weight, BMI, lean mass, fat
mass, waist circumference, hip circumference, blood pressure, heart rate and REE. Fat mass
and lean mass were determined using a bioimpedence analyzer (RJL Systems, Clinton Twp,
MI), indirect calorimetery (Body Gem by Health-e-Tech, Golden, CO) was used to measure
REE.
Metabolic Parameters
At baseline, 3, 9 and 24 months, laboratory analyses of plasma were performed to evaluate the
plasma markers of obesity (glucose, insulin, tumor necrosis factor alpha [TNF-α], high
sensitivity C-reactive protein [hs-CRP], free fatty acids [FFA], adiponectin, and leptin). Insulin
resistance was calculated using the Homeostasis Model of Assessment computer model
(HOMA2IR). 20 This protocol is further detailed in our previous publication. 14
Echocardiograms
Two-dimensional guided M-mode echocardiographic examinations were performed at
baseline, 3, 9 and 24 months using a Sequoia-C-512, (Acuson-Siemens, Malvern, PA).
Participants were studied in the left lateral decubitus position and images were acquired from
standard parasternal and apical windows. Myocardial contrast agents were utilized to improve
left ventricular endocardial delineation as necessary. All studies were read by two
echocardiologists blinded to all patient information. The echocardiographic measurements of
the LV internal dimension, interventricular septal and posterior wall diastolic thickness were
performed off line (Heartlab, Digisonics, Agfa Healthcare, Greenville, SC) on a dedicated echo
reading station according to recommendations of the American Society of Echocardiography
(ASE). 21
When M-mode measurements could not be obtained optimally, LV internal dimensions and
wall thickness measurements were made using the leading edge convention as described by
the ASE. LV end-diastolic and end-systolic volumes were calculated using the Teichholz
method.22 Relative wall thickness (RWT) was calculated as follows: RWT= [2 × LVPW]/Ded,
where LVPW = Left Ventricular posterior wall thickness at end diastole, and Ded=Left
Ventricular mid-cavity dimension at end diastole. LV end diastolic dimensions were used to
calculate left ventricular mass using a necropsy-validated formula. 23 The ratio of the left
ventricular mass over height (LVM/ ht 2.7) was calculated by dividing the left ventricular mass
by height in meters raised to the 2.7 power. 21
Statistical Analyses
Statistical analysis was performed with SigmaStat 3.0 (Systat Software, Inc., San Jose, CA).
We evaluated all of the study variables for conformation to normality using Q-Q plots,
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skewness and kurtosis statistics. Significantly non-normal variables were transformed prior to
analysis. Paired t-tests were performed to evaluate differences in outcomes between each visit.
Repeated-measures ANOVA with post-hoc comparisons and multiple comparison adjustments
were made across time point pairs by linear contrasts. Data are expressed as mean values plus
or minus the standard error of the mean and as the change in mean values from 0M to 3M, 3M
to 9M, and 9M to 24M post surgery with 95% confidence intervals. Pearson correlation
coefficients were prepared to evaluate the univariate relationships between variables.
RESULTS
Clinical Data
Significant physical and metabolic changes were observed as early as 1 month post surgery
(Figure 1A and B) and continued to be present throughout the entire two-year period. The
clinical, hemodynamic and metabolic data are summarized in Table 1.
All patients were severely obese at the start of the study (BMI 46.7 kg/m2) and experienced
significant weight reduction (from 126.7kg to 86.8 kg), yet remained clinically obese at 24
months following surgery (BMI 32.4 kg/m2) (Figure 1A). More specifically, the BMI
decreased by almost 8 kg/m2 in the initial 3 months post-operatively and 6.1 kg/m2 in the
subsequent 6 months (p<0.001) (Figure 1A). The rate of decline of the BMI in the 9- to 24-
month period slowed to just 0.9 kg/m2. Excess weight decreased by 31.5% in the first 3months
and by another 24.3% in the subsequent six months (p<0.001). There was no further decrease
thereafter (Table 1).
Waist circumference decreased by 13.9 cm in the first 3 months, and another 14.2 cm in the
subsequent 6 months (p<0.001). Hip circumference decreased in the first 9 months (26 cm,
p<0.001) while only nominally decreasing in the 9- to 24-month period (Table 1).
Fat mass decreased significantly in the first 3 months and insignificantly in the subsequent 6
months (15.5 kg and 12.1 kg, p<0.001) (Figure 1B). There was no further change subsequently.
Lean mass decreased in the first 3 months and once more in the subsequent 6 months (−4.9 kg
and −3.3 kg, respectively, P <.001, P= .002).
Hemodynamic Parameters—Systolic and diastolic blood pressures did not change over
the 24-month period (Table 1). However, before surgery all patients required antihypertensive
medications. These medications included thiazide diuretics, beta blockers, ACE inhibitors,
calcium channel blockers and angiotensin receptor blockers. Following surgery, the
requirements for antihypertensive medications decreased dramatically, with 13/15 patients off
all antihypertensive medications at 3 months. There was a trend for the heart rate to decrease
in the initial 3 months (from 79 to 69 beats per minute) and in the subsequent 6 months from
69 to 63 beats per minute, suggesting a decrease in sympathetic tone.
Metabolism—Resting energy expenditure decreased in the first 3 months as well as the
subsequent 6 months (−374 and −228 Cal/kg p<0.001) while increasing nominally in the 9- to
24-month period (Table 1).
Serum glucose levels fell from 110 ± 41 to 88 ± 40 mg/dL at 3 months. At 24 months the
average fasting glucose was 90 ± 18 mg/dL. Insulin levels declined most dramatically in the
initial three months (from 22.3 to 10.2 µU/mL), with a further decline over the subsequent six
months. HOMA2 IR indices declined most dramatically in the initial 3 month period (from 7.5
to 2.6).
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Adiponectin levels rose throughout the entire postoperative period with the most dramatic
increase between 9 and 24 months. In contrast, leptin levels declined most dramatically in the
first 3 months (from 53 to 29 ng/mL). The levels continued to decline over the subsequent 6
months but rose in the final 24-month period (from 17.3 to 26.3ng/mL). TNF alpha levels
increased in the first 3 months after surgery (from 7.9 to 8.6 pg/mL), most likely the result of
the surgical trauma. Thereafter, the levels declined in the subsequent study periods (to 6.5 and
2.9 pg/mL, respectively). Levels of hs-CRP declined in the initial 9 months of the study (from
0.6 to 0.4 to 0.2 mg/dL) and remained unchanged in the subsequent 15 months. FFA levels
increased in the initial 3 months (from 0.8 ± 0.2 to 1.0 ± 0.3 mmol/L), suggesting enhanced
rates of lipolysis. Thereafter, levels declined to 0.7 mmol/L and remained unchanged for the
subsequent 15 months.
Left Ventricular Mass—Figure 2A shows the decline of left ventricular mass as a function
of time after surgery. The greatest rate of decline was during the first 3 months. The rate of
decline slowed in the 3 to 9 and accelerated again between 9 to 24 month s. Thus, in contrast
to BMI, lean mass and fat mass, left ventricular mass continued to decline, in contrast to BMI
lean mass and fat mass. Figure 2B shows left ventricular mass as a function of lean mass at 9
months after surgery. There was a significant correlation between the two parameters at this
time point, suggesting that bigger people have bigger hearts. However, at the other time points
no such correlation existed (data not shown).
In order to assess the relationship between humoral factors and left ventricular mass, we
examined the fractional decline of left ventricular mass and the plasma markers of obesity after
surgery (Figure 3). Where left ventricular mass declines linearly, plasma markers change more
in a parabolic manner. Glucose, insulin, HOMA2-IR, leptin and hs-CRP all fell sharply from
their baseline in the first 3 months following surgery, plateau by 9 months and thereafter begin
to rise, but did not reach the pre-operative levels by 24 months.
DISCUSSION
We made the following observations: 1) weight decreased early after weight loss surgery, but
plateaued when patients were still obese; 2) left ventricular mass declined progressively, and
continued to decline at a linear rate for at least 24 months after weight loss surgery; 3) left
ventricular mass was overall insensitive to body composition, suggesting that the heart
continued to remodel even after body weight has reached a new plateau; and 4) systemic
metabolism normalized by 3 months, and remained so 24 months, after surgery.
Decrease in Left Ventricular Mass
The most striking finding in this study is the unexpected dissociation of the left ventricular
mass, BMI, fat mass and lean mass. Estimation of left ventricular mass offers prognositic
information beyond that of traditional cardiovascular risk factors.17, 24 In our cohort left
ventricular mass decreased in an almost linear fashion compared to the sharper “step” of the
lean mass at 1 month and of the fat mass at 6 months. However, the initial decline in left
ventricular mass (0 to 9 months) seemed less pronounced than the decline in BMI, fat mass,
and lean mass (Figure 1 and Figure 2). It is of interest that the first 3 months after surgery are
also the period of significant decline for glucose, insulin, HOMA2IR and hs-CRP. The rates
of decline for these plasma markers nadir by 9 months post surgery and begin to increase, while
the left ventricular mass deceases linearly over the entire 24-month period (Figure 3). In other
words, the heart continues to remodel long after the metabolic imbalances have been corrected.
In a short-term follow-up study severely obese adolescent patients with cardiac abnormalities
remained clinically obese after weight-loss surgery, but demonstrated a significant reversal of
their cardiac abnormalities. 11 There has also been a case report of a heart failure patient who
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underwent weight-loss surgery was removed from the heart transplant list and remained
clinically stable for at least eight years after the weight-loss surgery.13 However, none of the
studies examined the long-term effect of forced weight loss on left ventricular mass.
The benefits of weight-loss surgery on cardiac function are evident, but understanding the
pattern of change and the mechanisms behind reverse left ventricular remodeling remains
elusive. While the association between LVH, hypertension and increased afterload is well
established, only one study has shown that left ventricular mass significantly decreases in
normotensive obese patients, who lost weight and remained normotensive. 25 Our data concur
with this study. Neurohumoral determinants of left ventricular mass may be suspected in
patients who lose weight after bariatric surgery because hemodynamic changes alone cannot
account for the observed decreases in left ventricular mass. Although not investigated by us,
it seems reasonable to assume that an improvement in sleep disordered breathing may be
responsible for the decline in left ventricular mass. Evidence for the role of neurohumoral effect
on left ventricular mass can be found in the obstructive sleep apnea patients’ response to
continuous positive airway pressure (CPAP).26 Here regression of LVH and improved left
ventricular ejection fraction occurred as a result of abolition of cyclical surges in left ventricular
wall tension during sleep and chronic downward resetting of sympathetic outflow and
peripheral resistance secondary to the abolition of obstructive apnea.27, 28 It is well possible
that the patients we followed in this study experienced a decrease in frequency and severity of
sleep apnea.
Changes in Body Composition
Another major observation of this study is that after a rapid decline of lean mass by one month
after surgery, the lean mass and fat mass no longer move in parallel. Previous long-term studies
on the efficacy of weight-loss surgeries have reported weight regain and a return of co-morbid
conditions, such as diabetes, hypertension, and glucolipotoxicity.5, 10 We have observed earlier
that metabolic improvements are less pronounced in lap band patients compared to Roux-en-
Y patients.14 We and others also have observed that weight-relapse begins as early as 2 years
post-surgery depending on the type of weight loss surgery.29 Others have also shown that
overall mortality improves from obesity related complications, even while there is a regaining
of weight along with the return of obesity related co-morbidities.2, 3, 30, 31 While the exact
mechanisms behind the weight relapse are not known, some factors thought to play a role
include: a gradual dilatation of the gastric pouch in laparoscopic adjustable gastric banding,
32 increase of energy intake,10 and decreased physical activity over time.33, 34 We did not
observe weight regain and return of comorbid conditions in our cohort.
Systemic Metabolism
Metabolic dysregulation of obesity is accompanied by both adaptive and maladaptive responses
in the heart.35 Elevated FFA levels in patients with glucose intolerance or type 2 diabetes have
been associated with structural and functional changes in the heart.28, 36 The improvement in
FFA and adiponectin levels, as well as the normalization of glucose, insulin and leptin levels
in our cohort may play a role in the continued reduction of left ventricular mass, even at 24
months, despite no further weight loss. This issue requires further investigation.
CONCLUSIONS
Even though parameters of obesity, including BMI and body composition, plateau, the benefits
of bariatric surgery on metabolism and left ventricular mass are sustained. We propose that the
decline of left ventricular mass after weight loss surgery is regulated by neurohumoral factors.
No matter what the mechanism, the decline in left ventricular mass is likely to contribute to
the improved long-term survival of patients following weight loss surgery.
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Figure 1.
Figure 1A: Decline of the BMI over time. The rate of decline of BMI was greatest in the initial
6 months following surgery. Thereafter, the BMI continues to decline at a slower rate.
Figure 1B: Comparison of the Body Masses (fat mass and lean mass) after surgery. The
decrease in lean mass and fat mass was greatest during the first month after surgery. Lean mass
plateaued after 1 month, while fat mass continued to decrease sharply until 6 months and then
slowed over the subsequent months.
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Figure 2.
Figure 2A: Progressive decline in left ventricular mass (LVM): Left ventricular mass
declined progressively and normalized by 9 months (normal cut-off for women is 46.7 g/
m2.7).
Figure 2B: Correlation of left ventricular mass to lean mass at 9 months. Pearson’s
correlation indicated a strong correlation of left ventricular mass and lean mass at 9 months,
but not at other time period.
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Figure 3.
Fractional Change form Baseline of left ventricular mass and Plasma Markers of Obesity
after Bariatric Surgery: Left ventricular mass declines linearly over the 24-month time period
while plasma markers of obesity decline sharply in the initial 3 months and nadir at 9 months.
Thereafter the plasma markers begin to increase towards, but not to, the pre-operative levels.
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